learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Drug Eruptions
Any medication can cause skin reactions, some due to allergies and others due to dosage or genetic factors.
research Pharmacotherapy for Keloids and Hypertrophic Scars
Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.
research Compilation of a Comprehensive Gene Panel for Systematic Assessment of Genes That Govern an Individual’s Drug Responses
Researchers found that most genes affecting drug responses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.
research Lymphatic Vessel: Origin, Heterogeneity, Biological Functions, and Therapeutic Targets
Lymphatic vessels are essential for health and can be targeted to treat various diseases.
research Acitretin-Induced Repigmentation of Gray Hair: A Case Report
Acitretin treatment unexpectedly darkened a patient's gray hair.
Community Join
5 / 38 resultscommunity The likely cost of HMI-115, when it comes out
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
community Residents of Victoria, Australia, sign up for a monoclonal antibody clinical trial – potential cure
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.
community All Drugs in Clinical Trials in 2023
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Pyrilutamide PHASE 2 Results just one months to go. Are you excited???🤩
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.